ConductScience.org, home
PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus
API referenceFor AI assistants

Trial · NCT04300296

Participant flow42

How many started, completed or left each group, period by period.

1 to 20 of 42

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Treatment Period 1: Baseline to 16 WeeksSTARTEDAIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort25
Treatment Period 1: Baseline to 16 WeeksSTARTEDPlacebo in TP1 to AIN457 300 mg Q2W - TP 2 - CLP Cohort12
Treatment Period 1: Baseline to 16 WeeksSTARTEDAIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort24
Treatment Period 1: Baseline to 16 WeeksSTARTEDPlacebo in TP1 to AIN457 300 mg Q2W - TP 2 - MLP Cohort13
Treatment Period 1: Baseline to 16 WeeksSTARTEDAIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort24
Treatment Period 1: Baseline to 16 WeeksSTARTEDPlacebo in TP1 to AIN457 300 mg Q2W - TP 2 - LPP Cohort13
Treatment Period 1: Baseline to 16 WeeksPlacebo ResponderAIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort0
Treatment Period 1: Baseline to 16 WeeksPlacebo ResponderPlacebo in TP1 to AIN457 300 mg Q2W - TP 2 - CLP Cohort1
Treatment Period 1: Baseline to 16 WeeksPlacebo ResponderAIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort0
Treatment Period 1: Baseline to 16 WeeksPlacebo ResponderPlacebo in TP1 to AIN457 300 mg Q2W - TP 2 - MLP Cohort1
Treatment Period 1: Baseline to 16 WeeksPlacebo ResponderAIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort0
Treatment Period 1: Baseline to 16 WeeksPlacebo ResponderPlacebo in TP1 to AIN457 300 mg Q2W - TP 2 - LPP Cohort0
Treatment Period 1: Baseline to 16 WeeksCOMPLETEDAIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort23
Treatment Period 1: Baseline to 16 WeeksCOMPLETEDPlacebo in TP1 to AIN457 300 mg Q2W - TP 2 - CLP Cohort10
Treatment Period 1: Baseline to 16 WeeksCOMPLETEDAIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort24
Treatment Period 1: Baseline to 16 WeeksCOMPLETEDPlacebo in TP1 to AIN457 300 mg Q2W - TP 2 - MLP Cohort13
Treatment Period 1: Baseline to 16 WeeksCOMPLETEDAIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort23
Treatment Period 1: Baseline to 16 WeeksCOMPLETEDPlacebo in TP1 to AIN457 300 mg Q2W - TP 2 - LPP Cohort12
Treatment Period 1: Baseline to 16 WeeksNOT COMPLETEDAIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort2
Treatment Period 1: Baseline to 16 WeeksNOT COMPLETEDPlacebo in TP1 to AIN457 300 mg Q2W - TP 2 - CLP Cohort2

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04300296/flow

API referenceFor AI assistants